Product Code: ETC7551848 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Summon Dutta | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The India Pregabalin market is experiencing significant growth driven by increasing cases of neuropathic pain, epilepsy, and anxiety disorders in the country. Pregabalin, a medication used to treat these conditions, is gaining popularity due to its effectiveness in managing such disorders. The market is also witnessing a rise in demand for pregabalin as an off-label treatment for conditions such as fibromyalgia and restless leg syndrome. Factors such as a growing geriatric population, rising awareness about mental health issues, and expanding healthcare infrastructure are contributing to the market`s expansion. Key players in the India Pregabalin market include pharmaceutical companies like Pfizer, Glenmark Pharmaceuticals, and Intas Pharmaceuticals. The market is expected to continue its growth trajectory as the prevalence of chronic pain and neurological disorders increases in the country.
The India Pregabalin Market is experiencing significant growth due to the increasing prevalence of chronic pain conditions such as neuropathic pain, fibromyalgia, and epilepsy. The demand for pregabalin, a commonly prescribed medication for these conditions, is rising as awareness about its effectiveness and safety profile increases among healthcare professionals and patients. Additionally, the expanding geriatric population in India, who are more prone to these chronic pain conditions, is driving market growth. With the pharmaceutical industry focusing on product innovation and the introduction of generic versions of pregabalin, the market is becoming more competitive, leading to price variations and increased affordability for patients. Overall, the India Pregabalin Market is expected to continue its upward trajectory in the coming years.
In the India Pregabalin Market, some of the key challenges faced include intense competition among pharmaceutical companies leading to price wars, increasing regulatory scrutiny and changing guidelines impacting product approvals and market access, counterfeit products affecting brand reputation and patient safety, limited awareness and education about the drug among healthcare professionals and patients, and the presence of alternative treatment options impacting market growth. Additionally, the lack of proper reimbursement policies and insurance coverage for Pregabalin in India further hinders market penetration and patient affordability. Overcoming these challenges will require strategic pricing strategies, robust regulatory compliance measures, increased marketing efforts, and collaborations with healthcare providers to enhance product awareness and access.
The India Pregabalin Market presents promising investment opportunities due to the increasing prevalence of neurological disorders such as epilepsy, neuropathic pain, and anxiety disorders in the country. The growing awareness about mental health issues and the rising geriatric population are driving the demand for pregabalin-based medications. Additionally, the government`s initiatives to improve healthcare infrastructure and increase access to affordable healthcare services are further fueling market growth. Investors can explore opportunities in pharmaceutical companies involved in manufacturing and marketing pregabalin products, as well as companies specializing in research and development of innovative formulations. Partnerships with healthcare providers and distribution networks can also be lucrative avenues for investment in this growing market segment.
The Indian government regulates the Pregabalin Market through the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. Pregabalin is classified as a Schedule H drug, requiring a prescription for sale and purchase. The government also controls the pricing of Pregabalin through the National Pharmaceutical Pricing Authority (NPPA) to ensure affordability and accessibility. Additionally, the government mandates stringent quality control measures through the Central Drugs Standard Control Organization (CDSCO) to ensure the safety and efficacy of Pregabalin products in the market. Regulatory compliance, pricing regulations, and quality control measures are key factors shaping the India Pregabalin Market under government policies.
The India Pregabalin Market is expected to witness steady growth in the coming years due to increasing prevalence of chronic pain conditions such as neuropathic pain, fibromyalgia, and epilepsy. Factors such as a growing elderly population, rising awareness about mental health disorders, and changing lifestyle patterns leading to higher stress levels are driving the demand for pregabalin in India. Additionally, the expansion of healthcare infrastructure, increasing healthcare expenditure, and the availability of generic versions of pregabalin are contributing to market growth. However, challenges such as stringent regulatory requirements, competition from alternative treatment options, and potential side effects associated with pregabalin may hinder market growth to some extent. Overall, the India Pregabalin Market is poised for growth but will require strategic marketing efforts and a focus on product quality and safety to sustain long-term success.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 India Pregabalin Market Overview |
3.1 India Country Macro Economic Indicators |
3.2 India Pregabalin Market Revenues & Volume, 2021 & 2031F |
3.3 India Pregabalin Market - Industry Life Cycle |
3.4 India Pregabalin Market - Porter's Five Forces |
3.5 India Pregabalin Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.6 India Pregabalin Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.7 India Pregabalin Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 India Pregabalin Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of chronic pain conditions in India |
4.2.2 Growing awareness about the benefits of pregabalin in managing neuropathic pain |
4.2.3 Rising healthcare expenditure and improving healthcare infrastructure in the country |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for the approval and sale of pregabalin |
4.3.2 Competitive market landscape with the presence of alternative medications for pain management |
4.3.3 Concerns regarding potential side effects and abuse of pregabalin |
5 India Pregabalin Market Trends |
6 India Pregabalin Market, By Types |
6.1 India Pregabalin Market, By Application |
6.1.1 Overview and Analysis |
6.1.2 India Pregabalin Market Revenues & Volume, By Application, 2021- 2031F |
6.1.3 India Pregabalin Market Revenues & Volume, By Epilepsy, 2021- 2031F |
6.1.4 India Pregabalin Market Revenues & Volume, By Neuropathic Pain, 2021- 2031F |
6.1.5 India Pregabalin Market Revenues & Volume, By Anxiety Disorder, 2021- 2031F |
6.1.6 India Pregabalin Market Revenues & Volume, By Others, 2021- 2031F |
6.2 India Pregabalin Market, By Drug Class |
6.2.1 Overview and Analysis |
6.2.2 India Pregabalin Market Revenues & Volume, By Fibromyalgia Agents, 2021- 2031F |
6.2.3 India Pregabalin Market Revenues & Volume, By Anticonvulsants, 2021- 2031F |
6.2.4 India Pregabalin Market Revenues & Volume, By Others, 2021- 2031F |
6.3 India Pregabalin Market, By Distribution Channel |
6.3.1 Overview and Analysis |
6.3.2 India Pregabalin Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.3.3 India Pregabalin Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.3.4 India Pregabalin Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.3.5 India Pregabalin Market Revenues & Volume, By Others, 2021- 2031F |
7 India Pregabalin Market Import-Export Trade Statistics |
7.1 India Pregabalin Market Export to Major Countries |
7.2 India Pregabalin Market Imports from Major Countries |
8 India Pregabalin Market Key Performance Indicators |
8.1 Number of prescriptions for pregabalin by healthcare providers |
8.2 Patient adherence and persistence rates for pregabalin treatment |
8.3 Number of clinical trials and research studies on pregabalin efficacy and safety |
8.4 Adoption rates of pregabalin in different healthcare settings |
8.5 Patient satisfaction and reported outcomes with pregabalin treatment |
9 India Pregabalin Market - Opportunity Assessment |
9.1 India Pregabalin Market Opportunity Assessment, By Application, 2021 & 2031F |
9.2 India Pregabalin Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.3 India Pregabalin Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 India Pregabalin Market - Competitive Landscape |
10.1 India Pregabalin Market Revenue Share, By Companies, 2024 |
10.2 India Pregabalin Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |